Chronic hepatitis C Hepatocellular carcinoma
Conditions
Interventions
Low dose and long term treatment with Peg-Interferon alpha-2a
Conservertive treatment with drugs like UDCA
Sponsors
Department of Gastroenterology University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patient with HCC which were curatively treated with RFA. 2.Patient who tried the treatment for eradication of HCV, which was failed. 3.Neutrophil>750/mm3, Platelet, count>50,000, and Hemoglobin>8.5g/dL 4.Patient who was explained about the study, understood it, and gave the consent form.
Exclusion criteria
Exclusion criteria: Patient with 1.Drug allergy against Interferon. 2.Allergy against biological drugs. 3.Poorly controlled heart disease. 4.Extrahepatic metastasis of HCC 5.Active cancer of other organ. 6.Severe renal dysfunction; BUN>30mg/dL, or Cre>2.0mg/dL 7.on the herb treatment 8.other chronic liver disease like AIH or hepatitisB 9.Depression 10.on other clinical trial 11. any reason which medical doctor regard the patient as unsuitable for this test.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. HCC recurent rate 2. Time to recurrence | — |
Countries
Japan
Contacts
Public ContactYoshida, Hideo
University of Tokyo Department of Gastroenterology
Outcome results
None listed